Skip to main navigation menu Skip to main content Skip to site footer

No. 4 (2022)

ТЕРАПИЯ ШИЗОФРЕНИИ

Negative symptoms in schizophrenia: assessment approaches

https://doi.org/10.21265/PSYPH.2022.88.32.002

Published 2022-12-31

  • E.E. Tsukarzi

E.E. Tsukarzi
Moscow Research Institute of Psychiatry of the Ministry of Health of Russia

Abstract

The review article presents modern approaches to the systematics and diagnosis of negative symptoms in schizophrenia. Special attention is paid to the differentiation of primary and secondary negative symptoms, as well as the specification of negative symptoms detected during exacerbation of psychotic symptoms and with a predominance of negative symptoms. As a separate issue, criteria for the effectiveness of therapy for predominantly negative symptoms and quantitative indicators of minimal clinical improvement are considered. An analysis of the results of two studies conducted on the pooled database of studies of cariprazine in patients with schizophrenia with persitant negative symptoms is presented.Assessment of the predominantly negative symptoms is preferable to use the domain of negative symptoms of the PANSS scale, with the possibility of supplementing them with the BNSS and CAINS scales. Minimal clinical improvement in patients with predominantly negative symptoms is recorded with a reduction in the total score on the subscale of negative symptoms in the range from 7.3 to 18.5%.

Keywords

schizophrenia, negative symptoms, cariprazine, Positive and Negative Symptoms Scale (PANSS), minimum clinically important change of negative symptoms

PDF (Русский)

References

  1. Galderisi S., Bucci P., Mucci A. et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome // Schizophr Res. – 2013. – Vol. 147, No. 1. – P. 157–162.
  2. Mosolov S.N., Yaltonskaya P.A. Primary and Secondary Negative Symptoms in Schizophrenia // Front. Psychiatry, 2022; 12:766692. published: 03 January 2022 doi: 10.3389/fpsyt.2021.766692
  3. Strauss G.P., Horan W.P., Kirkpatrick B. et al. Deconstructing negative symptoms of schizophrenia: Avolition–apathy and diminished expression clusters predict clinical presentation and functional outcome // J Psychiatr Res. – 2013. – Vol. 47. – P. 783–790.
  4. Мосолов С.Н. Шкалы психометрической оценки симптоматики шизофрении и концепция позитивных и негативных расстройств. Москва, «Новый цвет», 2001.
  5. Millan M.J., Andrieux A., Bartzokis G. et al. Altering the course of schizophrenia: progress and perspectives // Nat Rev Drug Discov. – 2016. – Vol. 15. – P. 485–515.
  6. Kirkpatrick B. Developing Concepts in Negative Symptoms: Primary vs Secondary and Apathy vs Expression // J Clin Psychiatry. – 2014. – Vol. 75. – P. 3–7.
  7. Mucci A., Merlotti E., Üçok A. et al. Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases // Schizophr Res. – 2017. – Vol. 186. – P. 19–28.
  8. Еричев А.Н., Лутова Н.Б., Масленников Н.В., Мосолов С.Н., Оленева Е.В., Папсуев О.О., Цукарзи Э.Э., Шмуклер А.Б. Шизофрения Клинические рекомендации. Взрослые. Электронное издание. Минздрав РФ. Москва, 2021; 134 с. https://cr.minzdrav.gov.ru/recomend/451_2
  9. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia // Schizophr Bull. – 1987. – Vol. 13, No. 2. – P. 261–276.
  10. Bucci P., Galderisi S. Categorizing and assessing negative symptoms // Curr Opin Psychiatry. 2017;30:201–8.
  11. Falkai P., Dombi Z.B., Acsai K., et al. The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post-hoc analysis of 3 randomised, placebo-controlled trials // CNS Spectrum. 2021; 1-23.
  12. Németh G., Laszlovszky I., Czobor P. et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial // Lancet. – 2017. – Vol. 389, No. 10074. – P. 1103–1113.
  13. Demyttenaere K., Leenaerts N., Correll C.U., et al. Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms // Eur Psychiatry, 2021; 1-27.
  14. Mohr P., Cheng C., Claxton K, et al. The heterogeneity of schizophrenia in disease states // Schizophr. Res. 2004;71:83–95.
  15. Khan A., Liharska L., Harvey P., et al. Negative symptom dimensions of the positive and negative syndrome scale across geographical regions: implications for social, linguistic, and cultural consistency // Innov Clin Neurosci. 2017;14:30–40.
  16. Kring A., Gur R., Blanchard J., et al. The clinical assessment interview for negative symptoms (CAINS): final development and validation //Am J Psychiatry. 2013;170:165–72.
  17. Blanchard J., Cohen A. The Structure of Negative Symptoms Within Schizophrenia: Implications for Assessment // Schizophrenia Bulletin, 2006, vol. 32, No 2.- P. 238–245.
  18. Mucci A., Vignapiano A., Bitter I. et al. A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale // Eur Neuropsychopharmacol. – 2019. – Vol. 29, No. 8. – P. 947–959.85.
  19. Czobor P., Sebe B., Leucht S., et al. What is the minimum clinically important change in negative symptoms of schizophrenia? PANSS based post hoc analyses of a phase III clinical trial // Front. Psychiatry. 2022; 13: 816339. doi.org/10.3389/fpsyt.2022.816339
  20. Мосолов С.Н., Ялтонская П.А. Алгоритм терапии первичной негативной симптоматики при шизофрении // Современная терапия психических расстройств. – 2020. – No 2. – с. 2–10.

Downloads

Download data is not yet available.